内分泌治疗引起的血管舒缩症状在乳腺癌幸存者中很常见，也是治疗中断和生活质量降低的危险因素。 REALIZE 研究评估了患有血管舒缩症状的乳腺癌幸存者接受内分泌治疗（包括药物、生活方式改变和非处方产品）的真实治疗情况。在美国和五个欧洲国家（2020 年 2 月至 10 月）进行的分段时间点调查和图表审查。肿瘤学家提供了接受内分泌治疗（他莫昔芬或芳香酶抑制剂）诱发血管舒缩症状的成年乳腺癌幸存者的人口统计、临床和治疗数据；患者自愿完成关于症状严重程度、伴随睡眠和/或情绪症状、生活方式改变以及非处方产品使用情况的自我报告调查。患者特征；血管舒缩症状的严重程度；使用药品、改变生活方式和非处方产品（来自预先定义的清单）；总体而言，77 名肿瘤学家报告了 618 名乳腺癌幸存者的数据，其中 183 名 (29.6%) 填写了自我报告表。医生将 420 名 (68.0%) 女性归类为患有中度至重度血管舒缩症状，其中 66.9% 正在接受治疗。总共有 15.2% 的乳腺癌幸存者接受了全身激素治疗。文拉法辛 (24.7%)、西酞普兰 (16.5%) 和帕罗西汀 (13.6%) 是最常用的非激素药物。生活方式改变 (77.8%) 和非处方药 (61.6%) 很常见，特别是在伴有睡眠和/或情绪症状的患者中。尽管有禁忌症，但在寻求治疗的乳腺癌幸存者中，有相对较大比例的血管舒缩症状规定全身激素治疗。再加上患者报告的生活方式改变和非处方产品的大量使用，表明该人群需要缓解症状以及对具有既定安全性的新型非激素替代品的需求。版权所有 © 2024。由 Elsevier B.V. 出版。

Vasomotor symptoms induced by endocrine therapy are common in breast cancer survivors and a risk factor for therapy discontinuation and lower quality of life. The REALISE study evaluated the real-world treatment landscape in breast cancer survivors with vasomotor symptoms taking endocrine therapy, including pharmaceuticals, lifestyle changes, and over-the-counter products.Secondary analysis of the Adelphi Vasomotor Disease Specific Programme™, a large cross-sectional point-in-time survey and chart review conducted in the US and five European countries (February-October 2020). Oncologists provided demographic, clinical, and treatment data for adult breast cancer survivors with induced vasomotor symptoms taking endocrine therapy (tamoxifen or aromatase inhibitors); patients voluntarily completed self-report surveys on their symptom severity, concomitant sleep and/or mood symptoms, lifestyle changes, and use of over-the-counter products.Patient characteristics; vasomotor symptom severity; use of pharmaceuticals, lifestyle changes, and over-the-counter products (from pre-defined lists); lines of treatment.Overall, 77 oncologists reported data for 618 breast cancer survivors, of whom 183 (29.6 %) completed self-report forms. Physicians classified 420 (68.0 %) women as experiencing moderate-severe vasomotor symptoms, of whom 66.9 % were receiving treatment. In total, 15.2 % of all breast cancer survivors were prescribed systemic hormone therapy. Venlafaxine (24.7 %), citalopram (16.5 %), and paroxetine (13.6 %) were the most commonly prescribed nonhormonal medications. Lifestyle changes (77.8 %) and over-the-counter products (61.6 %) were common, especially in patients with concomitant sleep and/or mood symptoms.Despite contraindications, a relatively large proportion of treatment-seeking breast cancer survivors with vasomotor symptoms were prescribed systemic hormone therapy. This, combined with high patient-reported use of lifestyle changes and over-the-counter products, suggests a need for symptomatic relief and demand for new nonhormonal alternatives with established safety profiles in this population.Copyright © 2024. Published by Elsevier B.V.